
注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
亚盛医药集团是一家主要从事开发癌症、乙型肝炎病毒及若干衰老相关疾病的创新微型疗法的投资控股公司。该公司拥有自主研发的蛋白-蛋白相互作用靶向药物设计平台。该公司的主要产品包括下一代激酶抑制剂HQP1351,细胞凋亡靶向药物APG-1252、 APG2575、APG-115等。该公司于国内市场及美国等海外市场开展业务。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Hagop M. Kantarjian | - | 2023 | Member of Clinical Advisory Board |
Changqing Ye | 53 | 2019 | Independent Non-Executive Director |
Shaomeng Wang | 58 | 2017 | Co-Founder, Chief Scientific Advisor & Non-Executive Director |
Dajun Yang | 60 | 2009 | Co-Founder, Chairman & CEO |
Allen S. Lichter | 77 | 2023 | Chairman of the Clinical Advisory Board |
Jedd D. Wolchok | - | 2021 | Member of Clinical Advisory Board |
Wei Ren | 43 | 2019 | Independent Non-Executive Director |
Asher A. Chanan-Khan | - | 2023 | Member of Clinical Advisory Board |
Jiuyun Yu | 59 | 2024 | Independent Non-Executive Director |
Marina S. Bozilenko | 59 | 2024 | Independent Non-Executive Director |
Hagop M. Kantarjian | - | 2023 | Member of Clinical Advisory Board |
Arul M. Chinnaiyan | - | - | Member of Clinical Advisory Board |
Dazhong Lu | 56 | 2018 | Independent Non-Executive Director |
Paul A. Bunn | 79 | - | Member of Clinical Advisory Board |
David Sidransky | 65 | 2021 | Independent Non-Executive Director |
Marc Estes Lippman | 80 | 2025 | Independent Non-Executive Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核